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1. Introduction
Venoms are the secretion of venomous animals, which are synthesized and stored in specific
areas of their body i.e., venom glands. The animals use venoms for defense and/or to immo‐
bilize their prey. Most of the venoms are complex mixture of biologically active compounds
of different chemical nature such as multidomain proteins, peptides, enzymes, nucleotides,
lipids, biogenic amines and other unknown substances. Venomous animals as snakes, spi‐
ders, scorpions, caterpillars, bees, insects, wasps, centipedes, ants, toads and frogs have
largely shown biotechnological or pharmacological applications. During long-term evolu‐
tion, venom composition underwent continuous improvement and adjustment for efficient
functioning in the killing or paralyzing of prey and/or as a defense against aggressors or
predators. Different venom components act synergistically, thus providing efficiency of ac‐
tion of the components. Venom composition is highly species-specific and depends on many
factors including age, sex, nutrition and different geographic regions. Toxins, occurring in
venoms and poisons of venomous animals, are chemically pure toxic molecules with more
or less specific actions on biological systems [1-3]. A large number of toxins have been isolat‐
ed and characterized from snake venoms and snake venoms repertoire typically contain
from 30 to over 100 protein toxins. Some of these molecules present enzymatic activities,
whereas several others are non-enzymatic proteins and polypeptides. The most frequent en‐
zymes in snake venoms are phospholipases A2, serine proteinases, metalloproteinases, ace‐
tylcholinesterases, L-amino acid oxidases, nucleotidases and hyaluronidases. Higher
catalytic efficiency, heat stability and resistance to proteolysis as well as abundance of snake
venom enzymes provide them attractive models for biotechnologists, pharmacologists and
biochemists [3-4]. Scorpion toxins are classified according to their structure, mode of action,
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and binding site on different channels or channel subtypes. The venom is constituted by
mucopolysaccharides, hyaluronidases, phospholipases, serotonins, histamines, enzyme in‐
hibitors, antimicrobials and proteins namely neurotoxic peptides. Scorpion peptides
presents specificity and high affinity and have been used as pharmacological tools to charac‐
terize various receptor proteins involved in normal ion channel functionating, as abnormal
channel functionating in cases of diseases. The venoms can be characterized by identifica‐
tion of peptide toxins analysis of the structure of the toxins and also have proven to be
among the most and selective antagonists available for voltage-gated channels permeable to
K+, Na+, and Ca2+. The neurotoxic peptides and small proteins lead to dysfunction and pro‐
voke pathophysiological actions, such as membrane destabilization, blocking of the central,
and peripheral nervous systems or alteration of smooth or skeletal muscle activity [5-8]. Spi‐
der venoms are complex mixtures of biologically active compounds of different chemical na‐
ture, from salts to peptides and proteins. Specificity of action of some spider toxins is unique
along with high toxicity for insects, they can be absolutely harmless for members of other
taxons, and this could be essential for investigation of insecticides. Several spider toxins
have been identified and characterized biochemically. These include mainly ribonucleotide
phosphohydrolase, hyaluronidases, serine proteases, metalloproteases, insecticidal peptides
and phospholipases D [9-10]. Venoms from toads and frogs have been extensively isolated
and characterized showing molecules endowed with antimicrobial and/or cytotoxic activi‐
ties [11]. Studies involving the molecular repertoire of the venom of bees and wasps have
revealed the partial isolation, characterization and biological activity assays of histamines,
dopamines, kinins, phospholipases and hyaluronidases. The venom of caterpillars has been
partially characterized and contains mainly ester hydrolases, phospholipases and proteases
[12]. The purpose of this chapter is to present the main toxins isolated and characterized
from the venom of venomous animals, focusing on their biotechnological and pharmacolog‐
ical applications.
2. Biotechnological and pharmacological applications of snake venom
toxins
While the initial interest in snake venom research was to understand how to combat effects
of snakebites in humans and to elucidate toxins mechanisms, snake venoms have become a
fertile area for the discovery of novel products with biotechnological and/or pharmacologi‐
cal applications [13-14]. Since then, many different products have been developed based on
purified toxins from snake venoms, as well recent studies have been showing new potential
molecules for a variety of applications [15].
2.1. Toxins acting on cardiovascular system
Increase in blood pressure is often a transient physiological response to stressful stimuli,
which allows the body to react to dangers or to promptly increase activity. However, when
the blood pressure is maintained at high levels for an extended period, its long term effects
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are highly undesirable. Persistently high blood pressure could cause or accelerate multiple
pathological conditions such as organ (heart and kidney) failure and thrombosis events
(heart attack and stroke) [14]. So, it is important to lower the blood pressure of high-rick pa‐
tients through use of specific anti-hypertensive agents, and in this scenario, snake venom
toxins has been shown to be promising sources [14-15]. This is because it has long been not‐
ed that some snake venoms drastically lower the blood pressure in human victims and ex‐
perimental animals [15]. The first successful example of developing a drug from an isolated
toxin was the anti-hypertensive agent Capoten® (captopril), an angiotensin-converting en‐
zyme (ACE) inhibitor modeled from a venom peptide isolated from Bothrops jararaca venom
[16]. These bradykinin-potentiating peptides (BPPs) are venom components which inhibits
the breakdown of the endogenous vasodilator bradykinin while also inhibiting the synthesis
of the endogenous vasoconstrictor angiotensin II, leading to a reduction in blood pressure
[15]. BPPs have also been identified in Crotalus durissus terrificus venom [17]. Snake venom
represents one of the major sources of exogenous natriuretic peptides (NPs) [18]. The first
venom NP was identified from Dendroaspis angusticeps snake venom and was named Den‐
droaspis natriuretic peptide (DNP) [19]. Other venom NPs were also reported in various
snake species, such as Micrurus corallinus [20], B. jararaca [4], Trimeresurus flavoviridis, Trimer‐
esurus gramineus, Agkistrodon halys blomhoffii [21], Pseudocerastes persicus [22], Crotalus durissus
cascavella [23], Bungarus flaviceps [24], among others. L-type Ca2+-channels blockers identified
in snake venoms include calciseptine [25] and FS2 toxins [26] from Dendroaspis polylepis poly‐
lepis, C10S2C2 from D. angusticeps [27], S4C8 from Dendroaspis jamesoni kaimosae [28] and stej‐
nihagin, a metalloproteinase from Trimeresurus stejnegeri [29].
2.2. Toxins acting on hemostasis
Desintegrins are a family of cysteine-rich low molecular weight proteins that inhibits vari‐
ous integrins and that usually contain the integrin-binding RGD motif, that binds the GPIIa/
IIIb receptor in platelets, thus prevents the binding of fibrinogen to the receptor and conse‐
quently platelet aggregation [13]. Two drugs, tirofiban (Aggrastat®) and eptifibatide (Integ‐
rillin®) were designed based on snake venom disintegrins and are avaliable in the market as
antiplatelet agents, approved for preventing and treating thrombotic complications in pa‐
tients undergoing percutaneous coronay intervention and in patients with acute cornonary
sydrome [30-31]. Tirofiban has a non-peptide structure mimicking the RDG motif of the dis‐
integrin echistatin from Echis carinatus [30]. Eptifibatide is a cyclic peptide based on the KGD
motif of barbourin from Sisturus miliaris barbouri snake [31]. Recently, leucurogin, a new re‐
combinant disintegrin was cloned from Bothrops leucurus, being a potent agent upon platelet
aggregation [32]. Thrombin-like enzymes (TLEs) are proteases reported from many different
crotalid, viperid and colubrid snakes that share some functional similarity with thrombin
[13]. TLEs are not inactivated by heparin-antithrombin III complex (the physiological inhibi‐
tor of thrombin), and, differently to thrombin, they are not able to activate FXIII (the enzyme
that covalently cross-links fibrin monomer to form insoluble clots). These are interesting
properties, because although being procoagulants in vitro, TLEs have the clinical results of
being anti-coagulants, by the depletion of plasma level of fibrinogen, and the clots formed
are easily soluble and removed from the body. At same time, thrombolysis is enhanced by
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stimulation of endogenous plasminogen activators binding to the noncrosslinked fibrin [13].
Batroxobin (Defibrase®) was isolated and purified from Bothrops atrox venom [33] and an‐
crod (Viprinex®) from Agkistrodon rhodostoma [34]. Haemocoagulase® is a mixture of two pro‐
teinases isolated from B. atrox venom, acting on blood coagulation by two mechanisms: the
first having a thrombin-like activity and the second having a thromboplastin-like activity,
activating FX which in turn converts prothrombin into thrombin. It is indicated for the pre‐
vention and treatment of hemorrhages of a variety of origins [13]. Other toxins acting on he‐
mostasis with potential biotechnological/pharmacological applications has been purified
and characterized from several snake venoms, such as bhalternin from Bothrops alternatus
[35], bleucMP from B. leucurus [36], VLH2 from Vipera lebetina [37], trimarin from Trimeresu‐
rus malabaricus [38], BE-I-PLA2 from Bothrops erythromelas [39], among others.
2.3. Toxins with antibiotic activity
Antibiotics are a heterogeneous group of molecules produced by several organisms, includ‐
ing bacteria and fungi, presenting an antimicrobial profile, inducing the death of the agent or
inhibiting microbial growth [40]. L-amino acid oxidases (LAAOs) are enantioselective flavoen‐
zymes catalyzing the stereospecific oxidative deamination of a wide range of L-amino acids
to form α-keto acids, ammonia and hydrogen peroxide (H2O2). Antimicrobial activities are
reported to various LAAOs, such as TJ-LAO from Trimeresurus jerdonii [41], Balt-LAAO-I from
Bothrops alternatus  [42],  TM-LAO Trimeresurus mucrosquamatus  [43],  BpirLAAO-I from Bo‐
throps pirajai [44], casca LAO from Crotalus durissus cascavella [45], a LAAO from Naja naja oxiana
[46], BmarLAAO from Bothrops marajoensis [47], among others. Recently, studies revealed that
B. jararaca venom induced programmed cell death in epimastigotes of Trypanossoma cruzi, being
this anti-T. cruzi activity associated with fractions of venoms with LAAO activity [48]. Secret‐
ed phospholipases A2 (sPLA2s) constitute a diverse group of enzymes that are widespread in
nature, being particularly abundant in snake venoms. In addition to their catalytic activity,
hydrolyzing the sn-2 ester bond of glycerophospholipids, sPLA2s display a range of biologi‐
cal actions, which may be either dependent or independent of catalytic action [49]. Eight sPLA2
myotoxins purified from crotalid snake venoms, including both Lys49 and Asp49-type iso‐
forms, were all found to express bactericidal activity [50]. EcTx-I from Echis carinatus [51],
PnPLA2 from Porthidium nasutum [52] and BFPA [53] from Bungarus fasciatus also presented
antimicrobial activity. Vgf-1, a small peptide from Naja atra venom had in vitro activity against
clinically isolated multidrug-resistant strains of Mycobacterium tuberculosis [54]. Neuwiedase,
a metalloproteinase from Bothrops neuwiedi  snake venom, showed considerable effects of
Toxoplasma gondii infection inhibition in vitro [55]. Recently, a study revealed that whole venom,
crotoxin and sPLA2s (PLA2-CB and PLA2-IC) isolated from Crotalus durissus terrificus venom
showed antiviral activity against dengue and yellow fever viruses, which are two of the most
important arboviruses in public health [56].
2.4. Toxins acting on inflammatory and nociceptive responses
Various snake venoms are rich in secretory phospholipases A2 (sPLA2), which are potent
pro-inflammatory enzymes producing different families of inflammatory lipid mediators
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such as arachidonic acid derived eicosanoids, various lysophospholipids and platelet acti‐
vating factors through cyclooxygenase and lipoxygenase pathways [57]. In a recent study,
was described the first complete nucleotide sequence of a βPLI from venom glands of Lache‐
sis muta by a transcriptomic analysis [58]. Recently, was purified from the venom of Crotalus
durissus terrificus a hyaluronidase (named Hyal) that was able to provide a highly antiede‐
matogenic acitivity [59]. Crotapotin, a subunit of crotoxin, from C. d. terrificus, has been re‐
ported to possess immunossupressive activity, associated to an increase in the production of
prostaglandin E2 by macrophages, consequently reducing the proliferative response of lym‐
phocytes [60]. Various elapid and viperid venoms have been reported to induce antinocicep‐
tion through their neurotoxins and myotoxins [61]. C. d. terrificus venom induces
neurological symptoms in their victims, but, contrary to most venoms from other species, it
does not induce pain or severe tissue destruction at the site of inoculation, being usual the
sensation of paresthesia in the affected area [62]. Based on this, several studies have been
carried out with this venom, being reported in the literature several molecules with antinoci‐
ceptive activity from C. d. terrificus venom, such as crotamine [63] and crotoxin [64]. Has
been demonstrated that the anti-nociceptive effect of crotamine involve both central and pe‐
ripheral mechanisms, being 30-fold higher than the produced by morphine [63]. Studies
suggest that crotoxin has antinociceptive effect mediated by an action on the central nervous
system, without involvement of muscarinic and opioid receptors [64]. Other antinociceptive
peptides isolated from snake venoms are cobrotoxin, a neurotoxin isolated from Naja atra
[65] and hannalgesin, a neurotoxin isolated from Ophiophagus hannah [66].
2.5. Toxins acting on immunological system
Venom-derived peptides are being evaluated as immunosuppressants for the treatment of
autoimmune diseases and the prevention of graft rejection [67]. Studies have shown that an‐
ti-crotalic serum possesses an antibody content usually inferior to the antibody content of
other anti-venom serum suggesting that the crotalic venom is a poor immunogen or that it
has components with immunosuppressor activity [68]. Indeed, the immunosuppressive ef‐
fect of venom and crotoxin (a toxin isolated from Crotalus durissus terrificus) was reported
[68]. Crotapotin, an acidic and non-toxic subunit of crotoxin, administrated by intraperito‐
neal route, significantly reduces the severity of experimental autoimmune neuritis, an exper‐
imental model for Guillain-Barré syndrome, which indicate a novel path for neuronal
protection in this autoimmune disease and other inflammatory demyelinating neuropathies
[69]. Inappropriate activation of complement system occurs in a large number of inflamma‐
tory, ischaemic and other diseases. Cobra venom factor (CVF) is an unusual venom compo‐
nent which exists in the venoms of different snake species, such as Naja sp., Ophiophagus sp.
and Hemachatus sp. that activate complement system [70]. Due its similarity with C3 comple‐
ment system component, after binding to mammalian fB in plasma and cleavage of fB by fD,
produces a C3 convertase, that is more stable than the other C3 convertases, and resistant to
the fluid phase regulators. The CVF-Bb convertase consumes all plasma C3 obliterating the
functionality of complement system [70]. Recently, a CVF named OVF was purified from the
crude venom of Ophiophagus hannah and cloned by cDNA transcriptomic analysis of the
snake venom glands [71].
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2.6. Toxins with anticancer and cytotoxic activities
Anticancer therapy is an important area for the application of proteins and peptides from
venomous animals. Integrins play multiple important roles in cancer pathology including
tumor cell proliferation, angiogenesis, invasion and metastasis [72]. Inhibition of angiogene‐
sis is one of the heavily explored treatment options for cancer, and in this scenario snake
venom disintegrins represent a library of molecules with different structure, potency and
specificity [1]. RGD-containing disintegrins was identified in several snake venoms, inhibit‐
ing tumor angiogenesis and metastasis, such as accutin (from Agkistrodon acutus) [73], sal‐
mosin (from Agkistrodon halys brevicaudus) [74], contortrostatin (from Agkistrodon contortrix)
[75], jerdonin (from Trimeresurus jerdonii) [76], crotatroxin (from Crotalus atrox) [77], rhodos‐
tomin (from Calloselasma rhodostoma) [78] and a novel desintegrin from Naja naja [79]. The
cytostatic effect of L-amino acid oxidases (LAAOs) have been demonstrated using various
models of human and animal tumors. Studies show that LAAOs induces apoptosis in vascu‐
lar endothelial cells and inhibits angiogenesis [80]. Examples of LAAOs isolated from snake
venoms with anticancer potential are a LAAO isolated from Ophiophagus hannah [81],
ACTX-6 from A. acutus [82], OHAP-1 from Trimeresurus flavoviridis [83] and Bl-LAAO from
Bothrops leucurus [84]. Secretory phospholipases A2 (sPLA2) also figures the snake toxins
with anticancer potential [1]. sPLA2 with cytotoxic activity to tumor cells was described in
Bothrops neuwiedii [85], Bothrops brazili [86], Naja naja naja [87], among others. Crotoxin, the
main polypeptide isolated from C. d. terrificus has shown potent antitumor activity as well
the whole venom, highlighting thereby the potential of venom as a source of pharmaceutical
templates for cancer therapy [88]. BJcuL, a lectin purified from Bothrops jararacussu venom
[89] and a metalloproteinase [90] and a lectin from B. leucurus [91] are other examples of tox‐
ins from snake venoms with anticancer potential.
3. Biotechnological and pharmacological applications of scorpion venom
toxins
Scorpions are venomous arthropods, members of Arachnida class and order Scorpiones.
These animals are found in all continents except Antarctica, and are known to cause prob‐
lems in tropical and subtropical regions. Actually these animals are represented by 16 fami‐
lies and approximately 1500 different species and subspecies which conserved their
morphology almost unaltered [92-93]. The scorpion species that present medically impor‐
tance belonging to the family Buthidae are represented by the genera Androctonus, Buthus,
Mesobuthus, Buthotus, Parabuthus, and Leirus located in North Africa, Asia, the Middle East,
and India. Centruroides spp. are located in Southwest of United States, Mexico, and Central
America, while Tityus spp. are found in Central and South America and Caribbean. In these
different regions of the world the scorpionism is considered a public health problem, with
frequent statements that scorpion stings are dangerous [8]. It is generally known that scor‐
pion venom is a complex mixture composed of a wide array of substances. It contains muco‐
polysaccharides, hyaluronidase, phopholipase, low relative molecular mass molecules like
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serotonin and histamine, protease inhibitors, histamine releasers and polypeptidyl com‐
pounds. Scorpion venoms are a particularly rich source of small, mainly neurotoxic proteins
or peptides interacting specifically with various ionic channels in excitable membranes [94].
3.1. Toxins acting on cardiovascular system
The first peptide from scorpion endowed effects of bradykinin and on arterial blood pres‐
sure was isolated from the Brazilian scorpion Tityus serrulatus [95]. These peptides named
Tityus serrulatus Hypotensins have molecular masses ranging approximately from 1190 to
2700 Da [96]. Other scorpion bradykinin-potentiating peptides (BPPs) were reported to be
found in the venom of the scorpions Buthus martensii Karsch [97] and Leiurus quinquestriatus
[98]. These molecules can display potential as new drugs and could be of interest for bio‐
technological purposes.
3.2. Toxins with antibiotic activity
In order to defend themselves against the hostile environment, scorpions have developed
potent defensive mechanisms that are part of innate and adaptive immunity [99]. Cysteine-
free antimicrobial peptides have been identified and characterized from the venom of six
scorpion species [100]. Antimicrobial peptides isolated from scorpion venom are important
in the discovery of novel antibiotic molecules [101]. The first antimicrobial peptide isolated
from scorpions were of the defensin type from Leiurus quinquestriatus hebraeus [102]. Later
cytolitic and/or antibacterial peptides were isolated from scorpions belonging to the Buthi‐
dae, Scorpionidae, Ischnuridae, and Iuridae superfamilies hemo-lymph and venom
[103-108]. The discovery of these peptides in venoms from Eurasian scorpions, Africa and
the Americas, confirmed their widespread occurrence and significant biological function.
Scorpine, a peptide from Pandinus imperator with 75 amino acids, three disulfide bridges,
and molecular mass of 8350 Da has anti-bacterial and anti-malaria effects [104]. A cationic
amphipatic peptide consisting of 45 amino acids has been purified from the venom of the
southern African scorpion, Parabuthus schlechteri. At higher concentrations it forms non-se‐
lective pores into membranes causing depolarization of the cells [109]. Opistoporin1 and 2
(OP 1 and 2) was isolated from the venom of Opistophthalmus carinatus. These are amphi‐
pathic, cationic peptides which differ only in one amino acid residue. OP1 and PP were ac‐
tive against Gram-negative bacteria and both had hemolytic activity and antifungal activity.
These effects are related to membrane permeabilization [106]. A new antimicrobial peptide,
hadrurin, was isolated from Hadrurus aztecus. It is a basic peptide composed of 41 amino-
acid residues with a molecular mass of 4436 Da, and contains no cysteines. It is a unique
peptide among all known antimicrobial peptides described, only partially similar to the N-
terminal segment of gaegurin 4 and brevinin 2e, isolated from frog skin. It would certainly
be a model molecule for studying new antibiotic activities and peptide-lipid interactions
[110]. Pandinin 1 and 2 are antimicrobial peptides have been identified and characterized
from venom of the African scorpion Pandinus imperator [101]. Recently six novel peptides,
named bactridines, were isolated from Tityus discrepans scorpion venom by mass spectrome‐
try. The antimicrobial effects on membrane Na+ permeability induced by bactridines were
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observed on Yersinia enterocolitica [111]. The profile of gene in the venom glands of Tityus
stigmurus scorpions was studied by transcriptome. Data revealed that 41 % of ESTs belong
to recognized toxin-coding sequences, with transcripts encoding antimicrobial toxins (AMP-
like) being the most abundant, followed by alfa KTx-like, beta KTx-like, beta NaTx-like and
alfa NaTx-like. Parallel, 34% of the transcripts encode “other possible venom molecules”,
which correspond to anionic peptides, hypothetical secreted peptides, metalloproteinases,
cystein-rich peptides and lectins [7].
3.3. Toxins acting on acting on inflammatory and nociceptive response
The use of toxins as novel molecular probes to study the structure-function relationship of
ion-channels and receptors as well as potential therapeutics in the treatment of wide variety
of diseases is well documented. The high specificity and selectivity of these toxins have at‐
tracted a great deal of interest as candidates for drug development [8]. At least five peptides
have been identified from Buthus martensii (Chinese scorpion) venom that have anti-inflam‐
matory and antinociceptive properties [61]. One peptide, J123, blocks potassium channels
that activate memory T-cells [112]. The venom also contains a 61-amino acid peptide that
has demonstrated antiseizure properties in an animal model [113] as well as other constitu‐
ents that act as analgesics in mice, rats, and rabbits [114]. The polypeptide BmK IT2 from
scorpion Buthus martensi Karsh stops rats from reacting to experimentally-induced pain
[115]. A protein from the Indian black scorpion, Heterometrus bengalensis, bengalin caused
human leukemic cells to undergo apoptosis in vitro [116]. The peptide chlorotoxin, found in
the venom of the scorpion Leiurus quinquestriatus, retarded the activity of human glioma
cells in vitro [117]. An investigation about the role of kinins, prostaglandins and nitric oxide
in mechanical hypernociception, spontaneous nociception and paw oedema after intraplan‐
tar have been done with Tityus serrulatus venom in male wistar rats, proving the potential of
use of the venom to alleviate pain and oedema formation [118].
3.4. Toxins acting on acting on immunological system
OSK1 (alpha-KTx3.7) is a 38-residue toxin cross-linked by three disulphide bridges initial‐
ly purified from the venom of the central Asian scorpion Orthochirus scrobiculosus [119]. OSK1
and several structural analogues were produced by solid-phase chemical synthesis, and were
tested for lethality in mice and for their efficacy in blocking a series of 14 voltage-gated and
Ca2+ activated K+ channels in vitro. The literature report that OSK1 could serve as leads for
the design and production of new immunosuppressive drugs [119]. Margatoxin, a peptid‐
yl inhibitor of K+ channels has been purified to homogeneity from venom of the new world
scorpion Centruroides margaritatus showed that could be used as immunosuppressive agent
[120]. Kaliotoxin, a peptidyl inhibitor of the high conductance Ca2+-activated K+  channels
(KCa) has been purified to homogeneity from the venom of the scorpion Androctonus maur‐
etanicus mauretanicus. This peptide appears to be a useful tool for elucidating the molecu‐
lar pharmacology of the high conductance Ca2+-activated K+ channel [121]. Agitoxin 1, 2, and
3, from the venom of the scorpion Leiurus quinquestriatus var. hebraeus have been identi‐
fied on the basis of their ability to block the shaker K+ channel [122]. Hongotoxin, a pep‐
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tide inhibitor of shaker-type (K(v)1) K+ channels have been purified to homogeneity from
venom of the scorpion Centruroides limbatus [123]. Noxiustoxin, component II-11 from the
venom of scorpion Centruroides noxius Hoffmann, was obtained in pure form after fractiona‐
tion by Sephadex G-50 chromatography followed by ion exchange separation on carboxy-
methylcellulose columns. This peptide is the first short toxin directed against mammals and
the first  K+  channel blocking polypeptide-toxin found in scorpion venoms [124].  Pi1 is a
peptide purified and characterized from the venom of the scorpion Pandinus imperato, show‐
ing ability to block the shaker K+ channel [125]. All of these peptides obtained from scor‐
pions venoms are potential toxins acting on immunological system as immunosuppressant
for autoimmune diseases.
3.5. Toxins with anticancer and cytotoxic activities
One of the most notable active principles found in scorpion venom is chlorotoxin (Cltx), a
peptide isolated from the species Leiurus quinquestriatus. Cltx has 36 amino acids with four
disulfide bonds, and inhibits chloride influx in the membrane of glioma cells [126]. This pep‐
tide binds only to glioma cells, displaying little or no activity at all in normal cells. The toxin
appears to bind matrix metalloproteinase II [117]. A synthetic version of this peptide
(TM601) is being produced by the pharmaceutical industry coupled to iodine 131 (131I-
TM601), to carry radiation to tumor cells [127]. A recent study shows that TM601 inhibited
angiogenesis stimulated by pro-angiogenic factors in cancer cells, and when TM601 was co-
administered with bevacizumab, the combination was significantly more potent than a ten-
fold increase in bevacizumab dose [128]. A chlorotoxin-like peptide has also been isolated,
cloned and sequenced from the venom of another scorpion species, Buthus martensii Karsch
[129]. In reference [130] was expressed the recombinant chlorotoxin like peptide from Leiu‐
rus quinquestriatus and named rBmK CTa. Two novel peptides named neopladine 1 and neo‐
pladine 2 were purified from Tityus discrepans scorpion venom and found to be active on
human breast carcinoma SKBR3 cells. Inmunohistochemistry assays revealed that neopla‐
dines bind to SKBR3 cell surface inducing FasL and BcL-2 expression [131]. Results indicate
the venom from this scorpion represents a great candidate for the development of new clini‐
cal treatments against tumors.
3.6. Toxins with insecticides applications
Evidence for the potential application of scorpions toxins as insecticides has emerged in re‐
cent years. The precise action mechanism of several of these molecules remains unknown;
many have their effects via interactions with specific ion channels and receptors of neuro‐
muscular systems of insects and mammals. These highly potent and specific interactions
make venom constituents attractive candidates for the development of novel therapeutics,
pesticides and as molecular probes of target molecules [132].
Toxin Lqhα IT from the scorpion Leiurus quinquestriatus hebraeus venom is the best represen‐
tative of anti-insect alpha toxins [133-134]. A similar effect was observed after applying the
insect-selective toxin Bot IT1 from Buthus occitanus tunetanus venom [135]. Selective inhibi‐
tion of the inactivation process of the insect para/tipNav expressed in Xenopus oocyteswas
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was observed in the presence of Bjα IT [136] and OD1 [137], which are toxins from Buthotus
judaicus and Odonthobuthus doriae scorpion venom, respectively. A second group of scorpion
toxins slowing insect sodium channel inactivation was called alpha-like toxins. The first pre‐
cisely described toxins from this group were the Lqh III/Lqh3 (from L. q. hebraeus), Bom III/
Bom 3 and Bom IV/ Bom 4 (from B. o. mardochei). They were all tested on cockroach axonal
preparation [138-139]. BmKM1 toxin from B. martensi Karsch was the first alpha-like toxin
available in recombinant form that was tested also on cockroach axonal preparation [140].
Toxins Lqh6 and Lqh7 from L. q. hebraeus scorpion venom show high structural similarity
with Lqh3 toxin. Their toxicity to cockroach is in the range found for other alpha-like toxins
[141]. Alpha-like toxins from scorpion venoms show lower efficiency when applied to in‐
sects, as compared to α anti-insect toxins. Therefore they seem to be less interesting from the
point of view of future insecticide development [132]. Scorpion contractive and depressant
toxins are highly selective for insect sodium channels. Several of these toxins were tested on
cockroach axonal preparations; toxin AaH IT1 from the A. australis scorpion venom was the
first one [142-143]. All other contractive toxins tested on cockroach axon produced very sim‐
ilar effects, as for example Lqq IT1 from L. q. quinquestriatus [133]; Bj IT1 from B. judaicus
[143], Bm 32-1 and Bm 33-1 from B. martensi [144].
4. Biotechnological and pharmacological applications of spider venom
toxins
Spider venoms contain a complex mixture of proteins, polypeptides, neurotoxins, nucleic
acids, free amino acids, inorganic salts and monoamines that cause diverse effects in verte‐
brates and invertebrates [145]. Regarding the pharmacology and biochemistry of spider ven‐
oms, they present a variety of ion channel toxins, novel non-neurotoxins, enzymes and low
molecular weight compounds [146].
4.1. Toxins acting on cardiovascular system
Venom from the South American tarantula Grammostola spatulata presents GsMtx-4, a small
peptide belonging to the "cysteine-knot" family that blocks cardiac stretch-activated ion
channels and suppresses atrial fibrillation in rabbits [147]. Studies are being conducted to
develop therapeutics for atrial fibrillation based on GsMtx-4.
4.2. Toxins acting on hemostasis
ARACHnase (Hemostasis Diagnostics International Co., Denver, CO) is a normal plasma that
contains a venom extract from the brown recluse spider, Loxosceles reclusa, which mimics the
presence of a lupus anticoagulant (LA). ARACHnase is a biotechnological product useful‐
ness like a positive control for lupus anticoagulant testing [148]. Native dermonecrotic tox‐
ins (phospholipase-D) from Loxosceles sp. are agents that stimulate platelet aggregation [149].
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4.3. Toxins with antibiotic activity
Two peptide toxins with antimicrobial activity, lycotoxins I and II, were identified from ven‐
om of the wolf spider Lycosa carolinensis (Araneae: Lycosidae). The lycotoxins may play a
dual role in spider-prey interaction, functioning both in the prey capture strategy as well as
to protect the spider from potentially infectious organisms arising from prey ingestion. Spi‐
der venoms may represent a potentially new source of novel antimicrobial agents with im‐
portant medical implications [150].
4.4. Toxins acting on inflammatory and nociceptive response
Psalmotoxin 1, a peptide extracted from the South American tarantula Psalmopoeus cambridg‐
ei, has very potent analgesic properties against thermal, mechanical, chemical, inflammatory
and neuropathic pain in rodents. It exerts its action by blocking acid-sensing ion channel 1a,
and this blockade results in an activation of the endogenous enkephalin pathway [151].
Phospholipases from both Loxosceles laeta and Loxosceles reclusa cleaved LPC (lysophosphati‐
dylcholine) to LPA (lysophosphatidic acid) and choline. LPA receptors are potential targets
for Loxosceles sp. envenomation treatment [152]. The possibilities for biotechnological appli‐
cations in this area are enormous. Recombinant dermonecrotic toxins could be used as re‐
agents to establish a new model to study the inflammatory response, as positive inducers of
the inflammatory response and edema [9, 153-154]. The phospholipase-D from Loxosceles
venom could be used in phospholipid studies, specially studies on cell membrane constitu‐
ents with emphasis upon sphingophospholipids, lysophospholipids, lysophosphatidic acid
and ceramide-1-phosphate, as models for elucidating lipid product receptors, signaling
pathways and biological activities; this new wide field of Loxosceles research could also re‐
veal new targets for the treatment of envenomation [10].
4.5. Toxins acting on immunological system
The antiserum most commonly used for treatment of loxoscelism in Brazil is anti-arachnidic
serum. This serum is produced by the Instituto Butantan (São Paulo, Brazil) by hyperimmu‐
nization of horses with venoms of the spiders Loxosceles gaucho and Phoneutria nigriventer
and the scorpion Tityus serrulatus. Several studies have indicated that sphingomyelinase D
(SMase D) in venom of Loxosceles sp. spiders is the main component responsible for local
and systemic effects observed in loxoscelism [153, 155]. Neutralization tests showed that an‐
ti-SMase D serum has a higher activity against toxic effects of L. intermedia and L. laeta ven‐
oms and similar or slightly weaker activity against toxic biological effects of L. gaucho than
that of Arachnidic serum. These results demonstrate that recombinant SMase D can replace
venom for anti-venom production and therapy [155].
4.6. Toxins with anticancer and cytotoxic activities
Psalmotoxin 1 was evaluated on inhibited Na+ currents in high-grade human astrocytoma
cells (glioblastoma multiforme, or GBM). These observations suggest this toxin may prove
useful in determining whether GBM cells express a specific ASIC-containing ion channel
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type that can serve as a target for both diagnostic and therapeutic treatments of aggressive
malignant gliomas [156]. The antitumor activity of a potent antimicrobial peptide isolated
from hemocytes of the spider Acanthoscurria gomesiana, named gomesin, was tested in vitro
and in vivo. Gomesin showed cytotoxic and antitumor activities in cell lines, such as melano‐
ma, breast cancer and colon carcinoma [157].
4.7. Toxins with insecticides applications
Several spider toxins have been studied as potential insecticidal bioactive with great biotech‐
nological possible applications [10]. A component of the venom of the Australian funnel
web spider  Hadronyche  versuta  that  is  a  calcium channel  antagonist  retains  its  biological
activity when expressed in a heterologous system. Transgenic expression of this toxin in
tobacco effectively protected the plants from Helicoverpa armigera  and Spodoptera littoralis
larvae, with 100% mortality within 48h [158].  LiTxx1, LiTxx2 and LiTxx3 from Loxosceles
intermedia  venom were identified containing peptides that were active against Spodoptera
frugiperda. These venom-derived products open a source of insecticide toxins that could be
used as substitutes for chemical defensives and lead to a decrease in environmental prob‐
lems [159]. An insecticidal peptide referred to as Tx4(6-1) was purified from the venom of
the spider Phoneutria nigriventer  by a combination of gel filtration, reverse-phase fast liq‐
uid chromatography on Pep-RPC, reverse-phase high performance liquid chromatography
(HPLC) on Vydac C18 and ion-exchange HPLC. The protein contains 48 amino acids includ‐
ing 10 Cys and 6 Lys. The results showed that Tx4(6-1) has no toxicity for mice, and sug‐
gest that it is a specific anti-insect toxin [160]. SMase D and homologs in the SicTox gene
family are the most abundantly expressed toxic protein in venoms of Loxosceles and Sicar‐
ius spiders (Sicariidae). A recombinant SMase D from Loxosceles arizonica was obtained and
compared its enzymatic and insecticidal activity to that of crude venom. SMase D and crude
venom have comparable and high potency in immobilization assays on crickets. These da‐
ta indicate that SMase D is  a potent insecticidal  toxin,  the role for which it  presumably
evolved [161]. δ-PaluIT1 and δ-paluIT2 are toxins purified from the venom of the spider
Paracoelotes luctuosus. Similar in sequence to μ-agatoxins from Agelenopsis aperta, their phar‐
macological target is the voltage-gated insect sodium channel, of which they alter the inac‐
tivation properties in a way similar to α-scorpion toxins. Electrophysiological experiments
on the cloned insect voltage-gated sodium channel heterologously co-expressed with the
tipE subunit in Xenopus laevis oocytes, that δ-paluIT1 and δ-paluIT2 procure an increase of
Na+ current [162]. Recently, several toxins have been isolated from spiders with potential
biotechnological application as insecticide.
5. Biotechnological and pharmacological applications of toad and frog
toxins
Amphibians (toads, frogs, salamanders etc.) during their evolution have developed skin
glands covering most parts of their body surface. From these glands small amounts of a mu‐
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cous slime are secreted permanently, containing substances with different pharmacologic
activities such as cardiotoxins, neurotoxins, hypotensive as well as hypertensive agents, he‐
molysins, and many others. Chemically they belong to a wide variety of substance classes
such as steroids, alkaloids, indolalkylamines, catecholamines and low molecular peptides
[11, 163]. Several studies have been showing new potential molecules for a variety of phar‐
macological applications from toads and frogs venoms.
5.1. Toxins acting on cardiovascular system
Neurotensin-like peptides has been identified from frog skin, such as margaratensin, isolat‐
ed from Rana margaratae [164], a potential antihypertensive drug. Similar to the cardiac gly‐
cosides, bufadienolides from Bufo bufo gargarizans toad skin are able of inhibiting Na+/K+-
ATPase, having an important role on treatment of congestive heart failure and arterial
hypertension [165]. Examples of these bufadienolides are arenobufagin [166], cinobufagin,
bufalin, resibufogenin, among others [165]. In the skin of Rana temporaria and Rana igromacu‐
lata frogs, bradykinin, a hypotensive and smooth muscle exciting substance, has been found
[11]. Atelopidtoxin, a water-soluble toxin from skin of Atelopus zeteki frog, when injected into
mammals, produces hypotension and ventricular fibrillation [167]. Semi-purified skin ex‐
tracts from Pseudophryne coriacea frog displayed effects on systemic blood pressure, reducing
it by a probably cholinergic mechanism [168].
5.2. Toxins acting on hemostasis
Annexins are a well-known multigene family of Ca2+-regulated membrane-binding and
phospholipid-binding proteins. A novel annexin A2 (Bm-ANXA2) was isolated and purified
from Bombina maxima skin homogenate, being the first annexin A2 protein reported to pos‐
sess platelet aggregation-inhibiting activity [169].
5.3. Toxins with antibiotic activity
Toxins with antibiotic activity are the most well studied toxins in toads and frogs. Two anti‐
microbial bufadienolides, telocinobufagin and marinobufagin, were isolated from skin se‐
cretions of the Brazilian toad Bufo rubescens [170]. Antimicrobial peptides, named syphaxins
(SPXs), were isolated from skin secretions of Leptodactylus syphax frog [171]. The alkaloids
apinaceamine, 6-methyl-spinaceamine isolated from the skin gland secretions of Leptodacty‐
lus pentadactylus showed in screening tests bactericidal activity [172]. The cinobufacini and
its active components bufalin and cinobufagin, from Bufo bufo gargarizans Cantor skin, pre‐
sented anti-hepatitis B virus (HBV) activity [173]. Telocinobufagin from Rhinella jimi toad
were demonstrated to be active against Leishmania chagasi promastigotes and Trypanosoma
cruzi trypomastigotes, while hellebrigenin, from same source, was active against only T. cru‐
zi trypomastigotes [174].
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5.4. Toxins acting on inflammatory and nociceptive responses
Epibatidine, an azabicycloheptane alkaloid isolated from the skin of frog Epipedobates tricol‐
or, was found to be a potent antinociceptive compound. Although its toxicity, this toxin
could be a lead compound in the development of therapeutic agents for pain relief as well
for treatment of disorders whose pathogenesis involves nicotinic receptors [175]. A variety
of toxins acting on opioid receptors have been isolated from amphibians. Dermorphin (Tyr-
D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) and related heptapeptide [Hyp6]-dermorphin isolated
from the frog skin of Phyllomedusa sp., show higher affinity for μ-opioid receptors. Several
peptides belonging to the dermorphin family have been isolated from frog skin [61]. Deltor‐
phins (also referred as dermenkephalin) and related peptides isolated from the frog skin
have been found to exhibit high selectivity for δ-opiate receptors [176].
5.5. Toxins with anticancer and cytotoxic activities
Venenum Bufonis is a traditional Chinese medicine obtained from the dried white secretion of
auricular and skin glands of Chinese toads (Bufo melanostictus Schneider or Bufo bufo gargar‐
zinas Cantor). Cinobufagin (CBG), isolated from Venenum Bufonis, had potential immune
system regulatory effects and is suggested that this compound could be developed as a nov‐
el immunotherapeutic agent to treat immune-mediated diseases such as cancer [177]. Bufa‐
dienolides from toxic glands of toads are used as anticancer agents, mainly on leukemia
cells. Bufalin and cinobufagin from Bufo bufo gargarizans Cantor were tested and studies
shown that these toxins suppress cell proliferation and cause apoptosis in prostate cancer
cells via a sequence of apoptotic modulators [178]. Bufotalin, one of the bufadienolides iso‐
lated from Formosan Ch’an Su, which is made of the skin and parotid glands of toads, in‐
duce apoptosis in human hepatocellular carcinoma, probably involving caspases and
apopotosis-inducing factor [179]. Cutaneous venom of Bombina variegata pachypus toad pre‐
sented a cytolitic effect on the growth of the human HL 60 cell line [180]. Brevinin-2R, a non-
hemolytic defensin has been isolated from the skin of the frog Rana ridibunda, showing
pronounced cytotoxicity towards malignant cells [181].
5.6. Toxins with insulin releasing activity
Diabetes mellitus is a disease in which the body is unable to sufficiently produce or properly
use insulin. Newer therapeutic modalities for this disease are extremely needed. Peptides
with insulin-releasing activity have been isolated from the skin secretions of the frog Aga‐
lychnis litodryas and may serve as templates for a novel class of insulin secretagogues [182].
6. Biotechnological and pharmacological applications of bee and wasp
toxins
Stinging accidents caused by wasps and bees generally produce severe pain, local damage
and even death in various vertebrates including man, caused by action of their venoms. Bee
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venom contains a variety of compounds peptides including melittin, apamin, adolapin, and
mast cell degranulating (MCD) peptide, in addition of hyaluronidase and phospholipase A
enzymes, that plays a variety of biological activities. The chemical constituents of venoms
from wasps species include acetylcholine, serotonin, norepinephrine, hyaluronidase, histi‐
dine decarboxylase, phospholipase A2 and several polycationic peptides and proteins [12].
6.1. Toxins acting on cardiovascular system
Honey bee venom and its main constituents have a marked effect on the cardiovascular system,
most notably a fall in arterial blood pressure [183]. From the hemodynamic point of view, the
venom, in higher doses, is extremely toxic to the circulatory system and in smaller doses,
however, produce a stimulatory effect upon the heart [184]. Melittin, a strongly basic 26 amino-
acid polypeptide which constitutes 40–60% of the whole dry honeybee venom, induces con‐
tractures and depolarization in skeletal muscle [12]. Melittin is cardiotoxic in vitro, causing
arrest of the rat heart, but only induces a slight hypertension in vivo [183]. Apamin, without
direct effect on contraction or relaxation, could attenuate the relaxation evoked by melittin at
lower concentrations, and thus contribute to the conversion of melittin’s relaxing activity into
the contractile activity of the venom. Another peptide found in bee venom that outlines effects
on the cardiovascular system is the Cardiopep. Cardiopep is a relatively nonlethal compo‐
nent, compared to phospholipase A, melittin, or whole bee venom itself. It is a potent nontox‐
ic  beta-adrenergio-like  stimulant  that  possesses  definite  anti-arrhythmic properties  [185].
Studies on the cardiovascular effects of mastoparan B, isolated from the venom of the hor‐
net Vespa basalis, has shown that the peptide caused a dose-dependent inhibition of blood
pressure and cardiac function in the rat. Research has shown that the cardiovascular effects
of mastoparan B are mainly due to the actions of serotonin, and by a lesser extent to other
autacoids, released from mast cells as well from other biocompartments [186].
6.2. Toxins acting on hemostasis
The mechanism by which bee venom affects the hemostatic system remains poorly under‐
stood [187]. Among the serine proteases isolated from bees, which acts as a fibrin(ogen)olyt‐
ic enzyme, activator prothrombin and directly degrades fibrinogen into fibrin degradation
products, are the Bi-VSP (Bombus ignitus) [188], Bt-VSP (Bombus terrestris) [189] and Bs-VSP
(Bombus hypocrita sapporoensis) [190]. According reference [188], the activation of prothrom‐
bin and fibrin(ogen)olytic activity may cooperate to effectively remove fibrinogen, and thus
reduce the viscosity of blood. The injection fibrin(ogen)olytic enzyme can be used to facili‐
tate the propagation of components of bee venom throughout the bloodstream of mammals.
Bumblebee venom also affects the hemostatic system through by Bi-KTI (B. ignitus), a Ku‐
nitz-type inhibitor, that strongly inhibited plasmin during fibrinolysis, indicating that Bi-
KTI specifically targets plasmin [187]. A toxin protein named magnvesin was purified of
Vespa magnifica. This protein contains serine protease-like activity inhibits blood coagulation,
and was found to act on factors TF, VII, VIII, IX and X [191]. Other anticoagulant protein
(protease I) with proteolytic activity was purified from Vespa orientalis venom, involving
mainly coagulation factors VIII and IX [192]. Magnifin, a phospholipase A1 (PLA1) purified
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from wasp venoms of V. magnifica, is very similar to other (PLA1), especially to other wasp
allergen PLA1. Magnifin can activate platelet aggregation and induce thrombosis in vivo. It
was the first report of PLA1 from wasp venoms that can induce platelet aggregation [193].
6.3. Toxins with antibiotic activity
Antimicrobial peptides have attracted much attention as a novel class of antibiotics, espe‐
cially for antibiotic-resistant pathogens. They provide more opportunities for designing nov‐
el and effective antimicrobial agents [194]. Melittin has various biological, pharmacological
and toxicological actions including antibacterial and antifungal activities [195]. Bombolitin
(structural and biological properties similar to those of melittin), isolated from the venom of
B. ignitus worker bees, possesses antimicrobial activity and show inhibitory effects on bacte‐
rial growth for Gram-positive, Gram-negative bacteria and fungi, suggesting that bomboli‐
tin is a potential antimicrobial agent [196]. Osmin, isolated of solitary bee Osmia rufa, shows
some similarities with the mast cell degranulation (MCD) peptide family. Free acid and C-
terminally amidated osmins were chemically synthesized and tested for antimicrobial and
haemolytic activities. Antimicrobial and antifungal tests indicated that both peptides were
able to inhibit bacterial and fungal growth [197]. Two families of bioactive peptides which
belongs to mastoparans (12a and 12b) and chemotactic peptides (5e, 5g and 5f) were purified
and characterized from the venom of Vespa magnifica. MP-VBs (vespa mastoparan) and
VESP-VBs (vespa chemotactic peptide) were purified from the venom of the wasp Vespa bi‐
color Fabricius and demonstrated antimicrobial action [198]. The amphipathic α-helical
structure and net positive charge (which permits electrostatic interaction with the negatively
charged microbial cell membrane) of mastoparan appear to be critical for MCD activity and
because of these structural properties, mastoparans are often highly active against the cell
membranes of bacteria, fungi, and erythrocytes, as well as mast cells [199].
6.4. Toxins acting on inflammatory and nociceptive responses
Bee venom has been used in Oriental medicine and evidence from the literature indicates
that bee venom plays an anti-inflammatory or anti-nociceptive role against inflammatory re‐
actions associated with arthritis and other inflammatory diseases [200]. Bee venom demon‐
strated neuroprotective effect against motor neuron cell death and suppresses
neuroinflammation-induced disease progression in symptomatic amyotrophic lateral sclero‐
sis (ALS) mice model [200]. Melittin has effects on the secretion of phospholipase A2 and in‐
hibits its enzymatic activity, which is important because phospholipases may release
arachidonic acid which is converted into prostaglandins [201]. Have also been reported that
melittin decreased the high rate of lethality, attenuated hepatic inflammatory responses, al‐
leviated hepatic pathological injury and inhibited hepatocyte apoptosis. Protective effects
were probably carried out through the suppression of NF-jB activation, which inhibited
TNF-α liberation. Therefore, melittin may be useful as a potential therapeutic agent for at‐
tenuating acute liver injury [202]. In addition of melittin, others agents has shown anti-in‐
flammatory activity. Among them are adolapin and MCDP. Adolapin showed marked anti-
inflammatory and anti-nociceptive properties due to inhibition of prostaglandin synthase
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system [203]. MCDP, isolated of Apis mellifera venom, is a strong mediator of mast cell de‐
granulation and releases histamine at low concentrations [204].
6.5. Toxins acting on immunological system
Characterization of the primary structure of allergens is a prerequisite for the design of new
diagnostic and therapeutic tools for allergic diseases. Major allergens in bee venom (recog‐
nized by IgE in more than 50% of patients) include phospholipase A2 (PLA2), acid phospha‐
tase, hyaluronidase and allergen C, as well as several proteins of high molecular weights
(MWs) [205]. Besides these, Api m 6, was frequently (42%) recognized by IgE from bee ven‐
om hypersensitive patients [206]; from wasp venom were purified Vesp c 1 (phospholipase
A1) and Vesp c 5 (antigen-5) from Polistes gallicus, and Vesp ma 2 and Vesp ma 5 from Vespa
magnifica, [207-208]. Formulations of poly(lactic-co-glycolic acid) (PLGA) microspheres rep‐
resent a strategy for replacing immunotherapy in multiple injections of venom. The results
obtained with bee venom proteins encapsulated showed that the allergens may still be effec‐
tive in the induction of an immune response and so may be a new formulation for VIT [209].
Recombinant proteins with immunosuppressive properties have been reported in the litera‐
ture, such as rVPr1 and rVRr3, identified, cloned and expressed from isolated VPR1 and
VPr2 from Pimpla hypochondriaca [210]. Chemotactic peptide protonectin 1-6 (ILGTIL-NH2)
was detected in the venom of the social wasp Agelaia pallipes pallipes [211]. Polybia-MPI and
Polybia-CP were isolated from the venom of the social wasp Polybia paulista and character‐
ized as chemotactic peptides for PMNL cells [212]. Under the diagnosis, the microarray was
reported. Protein chips can be spotted with thousands of proteins or peptides, permitting to
analyses the IgE responses against a tremendous variety of allergens. First attempts to mi‐
croarray with Hymenoptera venom allergens included Api m 1, Api m 2, Ves v 5, Ves g 5
and Pol a 5 in a set-up with 96 recombinant or natural allergen molecules representative of
most important allergen sources. The venom allergens from different bee, wasp and ant spe‐
cies can be offered on a single chip, allowing to differentiate the species that has stung based
on species-specific markers. The allergen microarray allows the determination and monitor‐
ing of allergic patients’ IgE reactivity profiles to large numbers of disease-causing allergens
by using single measurements and minute amounts of serum [213].
6.6. Toxins with anticancer and cytotoxic activities
Bee venom is the most studied among the arthropods covered in this chapter regarding its
anti-cancer activities, due mainly to two substances that have been isolated and character‐
ized: melittin and phospholipase A2 (PLA2). Melittin and PLA2 are the two major compo‐
nents in the venom of the species Apis mellifera [214]. Melittin is inhibitor of calmodulin
activity and is an inhibitor of cell growth and clonogenicity of human and murine leukemic
cells [215]. Study indicated that key regulators in bee venom-induced apoptosis are Bcl-2
and caspase-3 in human leukemic U937 cells through down-regulation of the ERK and Akt
signal pathway [216]. Furthermore recent reports indicate that BV is also able to inhibit tu‐
mor growth and exhibit anti-tumor activity in vitro and in vivo and can be used as a chemo‐
therapeutic agent against malignancy [217]. The adjuvant treatment with PLA2 and
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phosphatidylinositol-(3,4)-bisphosphate was more effective in the blocking of tumor cell
growth [218]. New peptides have been isolated from bee venom and tested in tumor cells,
exhibiting promising activities in the treatment of cancer. Lasioglossins isolated from the
venom of the bee Lasioglossum laticeps exhibited potency to kill various cancer cells in vitro
[219]. Briefly the bee venom acts inhibiting cell proliferation and promoting cell death by
different means: increasing Ca2+ influx; inducing cytochrome C release; binding calmodulin;
decreasing or increasing the expression of proteins that control cell cycle or activating PLA2,
causing damage to cell membranes interfering in the apoptotic pathway [220]. Among po‐
tential anticancer compounds, one of the most studied is mastoparan, peptide isolated from
wasp venom that has been reported to induce a potent facilitation of the mitochondrial per‐
meability transition. It should be noted that this recognized action of mastoparan is marked
at concentrations <1 μM [221]. Two novel mastoparan peptides, Polybia-MP-II e Polybia-
MP-III isolated from venom of the social wasp Polybia paulista, exhibited hemolytic activity
on erythrocytes [222]. Polybia-MPI, also was purified from the venom of the social wasp P.
paulista, synthesized and studied its antitumor efficacy and cell selectivity. Results revealed
that polybia-MPI exerts cytotoxic and antiproliferative efficacy by pore formation and have
relatively lower cytotoxicity to normal cells [223].
6.7. Toxins with insulin releasing activity
Bee venom inhibits insulitis and development of diabetes in non-obese diabetic (NOD) mice.
The cumulative incidence of diabetes at 25 weeks of age in control was 58% and NOD mice
bee venom treated was 21% [224]. Mastoparan, component of wasp venom, is known to af‐
fect phosphoinositide breakdown, calcium influx, exocytosis of hormones and neurotrans‐
mitters and stimulate the GTPase activity of guanine nucleotide-binding regulatory proteins
[225]. Thus, it is reported in the literature that mastoparan stimulates insulin secretion in hu‐
man, as well as in rodent. Furthermore, glucose and alpha-ketoisocaproate (alfa-KIC) in‐
crease the mastoparan-stimulated insulin secretion [226].
7. Biotechnological and pharmacological applications of ant, centipede
and caterpillar venom toxins
Ant, centipede and caterpillar venoms have not been studied so extensively as the venoms
of snakes, scorpions and spiders. Ant venoms are rich in the phospholipase A2 and B, hya‐
luronidase, and acid and alkaline phosphatase as well as in histamine itself [227]. Centipede
venoms have been poorly characterized in the literature. Studies have reported in centipede
venoms the presence of esterases, proteinases, alkaline and acid phosphatases, cardiotoxins,
histamine, and neurotransmitter releasing compounds in Scolopendra genus venoms [228].
Among the most studied caterpillar venoms are Lonomia obliqua and Lonomia achelous ven‐
oms, which cause similar clinical effects [229]. Based on cDNA libraries, was possible to
identify several proteins from L. obliqua, such as cysteine proteases, group III phospholipase
A2, C-type lectins, lipocalins, in addition to protease inhibitors including serpins, Kazal-type
inhibitors, cystatins and trypsin inhibitor-like molecules [230].
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7.1. Toxins acting on cardiovascular system
A study showed that the Lonomia obliqua caterpillar bristles extract (LOCBE) directly releas‐
es kinin from low-molecular weight kininogen, being suggested that kallikrein-kinin system
plays a role in the edematogenic and hypotensive effects during L. obliqua envenomation [231].
7.2. Toxins acting on hemostasis
There are numerous studies in literature reporting the effects on the hemostatic system of
toxins from caterpillars. The effect of a crude extract of spicules from Lonomia obliqua cater‐
pillar on hemostasis was found to activate both prothrombin and factor X [232]. Lopap is a
prothrombin activator isolated from the bristles of L. obliqua caterpillar. Lopap demonstrated
ability to induce activation, expression of adhesion molecules and to exert an anti-apoptotic
effect on human umbilical vein endothelial cells [233]. Lonofibrase, an α-fibrinogenase from
L. obliqua was isolated from venomous secretion [234]. Losac, a protein with procoagulant
activity, which acts as a growth stimulator and an inhibitor of cellular death for endothelial
cells, was purified of the bristle extract of L. obliqua. Losac may have biotechnological appli‐
cations, including the reduction of cell death and consequently increased productivity of an‐
imal cell cultures [235]. Lonomin V, serine protease isolated from Lonomia achelous
caterpillar, inhibited platelet aggregation, probably caused by the degradation of collagen. It
is emphasized that Lonomin V shows to be a potentially useful tool for investigating cell-
matrix and cell-cell interactions and for the development of antithrombotic agents in terms
of their anti-adhesive activities [236]. The venom from the tropical ant, Pseudomyrmex triplar‐
inus, inhibited arachidonic acid and induced platelet aggregation, suggesting that venom
prevented the action of prostaglandins. The venom was fractionated and factor F (adeno‐
sine) with antiplatelet activity were detected [237].
7.3. Toxins with antibiotic activity
Venom alkaloids from Solenopsis invicta, fire ant, inhibit the growth of Gram-positive and
Gram-negative bacteria and presumably act as a brood antibiotic. Peptides named poneri‐
cins were identified from the venom of ant Pachycondyla goeldii. Fifteen peptides were classi‐
fied into three different families according to their primary structure similarities: ponericins
G, W, and L. Ponericin G1, G3, G4 and G6 demonstrated antimicrobial activity. Ponericins G
share about 60% sequence similarity with cecropins and these have a broad spectrum of ac‐
tivity against bacteria. Peptides family W shares about 70% sequence similarity with Gae‐
gurin 5 (Rana rugosa) and melittin (discussed in previous topics). Gaegurin 5 exhibits a
broad spectrum of antimicrobial action against bacteria, fungi, and protozoa and has very
little hemolytic action. The ponericin L2 from the third family has only an antibacterial ac‐
tion, and shares important sequence similarities with dermaseptin 5, which has strong anti‐
microbial action against bacteria, yeast, fungi, and protozoa [238]. A cytotoxic peptide from
the venom of the ant Myrmecia pilosula, Pilosulin 1, was identified as a potential novel anti‐
microbial peptide sequence. It outlined a potent and broad spectrum antimicrobial activity
including standard and multi-drug resistant gram-positive and gram-negative bacteria and
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Candida albicans [239]. Two antimicrobial peptides from centipede venoms, scolopin 1 and 2
were identified from venoms of Scolopendra subspinipes mutilan [240].
7.4. Toxins acting on inflammatory and nociceptive responses
Venom from the tropical ant Pseudomyrex triplarinus relieves pain and inflammation in rheu‐
matoid arthritis [241]. Venom from the P. triplarinus contains peptides called myrmexins
that relieve pain and inflammation in patients with rheumatoid arthritis and inhibit inflam‐
matory carragenin-induced edema in mice [242].
7.5. Toxins acting on immunological system
The most frequent cause of insect venom allergy in the Southeastern USA is the imported
fire ant and the allergens are among the most potent known. Fire ant venom is a potent al‐
lergy-inducing agent containing four major allergens, Sol i I, Sol i II, Sol i III and Sol i IV
[243-244].
7.6. Toxins with anticancer and cytotoxic activities
Solenopsin A, a primary alkaloid from the fire ant Solenopsis invicta, exhibits antiangiogenic
activity. Among the results obtained in this study, one of the most interesting was the selec‐
tive inhibition of Akt by solenopsin in vitro, that is of great interest since few Akt inhibitors
have been developed, and Akt is a key molecular target in the pharmacological treatment of
cancer [245]. Glycosphingolipid 7, identified in the millipede Parafontaria laminata armigera,
suppressed cell proliferation and this effect was associated with suppression of the activa‐
tion of FAK (focal adhesion kinase), Erk (extracellular signal-regulated kinase), and Akt in
melanoma B16F10 cells. Cells treated with glycosphingolipid 7 reduced the expression of the
proteins responsible for the progression of cell cycle, cyclin D1 and CDK4 [246].
7.7. Toxins with insecticides applications
Peptides named ponericins from ant Pachycondyla goeldii have a marked action as insecti‐
cides. Among the peptides showed insecticidal activity are the ponericins G1, G2 and poner‐
icins belonging to the family W [238].
In Table 1, is presented a summary of the main biotechnological/pharmacological applica‐
tions of toxins from venomous animals covered in this chapter.
Source Toxin Application Ref.
Toxins acting on cardiovascular system
Snakes Agkistrodon halys
blomhoffii
NP Anti-hypertensive agent [21]
Bothrops jararaca BPP Anti-hypertensive agent (development of
captopril and derivatives)
[16]
An Integrated View of the Molecular Recognition and Toxinology - From Analytical Procedures to Biomedical
Applications
42
NP Anti-hypertensive agent [4]
Bungarus flaviceps NP Anti-hypertensive agent [24]
Crotalus durissus
cascavella
NP Anti-hypertensive agent [23]
Crotalus durissus
terrificus
BPP Anti-hypertensive agent [17]
Dendroaspis
angusticeps
DNP Anti-hypertensive agent: natriuretic peptide [19]
C10S2C2 Anti-hypertensive drug: L-type Ca2+channels
blocker
[27]
Dendroaspis jamesoni
kaimosae
S4C8 Anti-hypertensive agent: L-type
Ca2+channels blocker
[27]
Dendroaspis polylepis
polylepis
Calciseptine Anti-hypertensive agent: L-type
Ca2+channels blocker
[25]
FS2 toxins Anti-hypertensive agent: L-type
Ca2+channels blocker
[26]
Micrurus corallinus NP Anti-hypertensive agent [20]
Pseudocerastes
persicus
NP Anti-hypertensive agent [22]
Trimeresurus
flavoviridis
NP Anti-hypertensive agent [21]
Trimeresurus
stejnegeri
Stejnihagin Anti-hypertensive agent: L-type
Ca2+channels blocker
[29]
Scorpions Buthus martensii BPP Anti-hypertensive agent [97]
Leiurus
quinquestriatus
BPP Anti-hypertensive agent [98]
Tityus serrulatus BPP Anti-hypertensive agent [96]
Spiders Grammostola
spatulata
GsMtx-4 Blocks cardiac stretch-activated ion channels
and suppresses atrial fibrillation in rabbits
[147]
Toads and Frogs Atelopus zeteki Atelopidtoxin Hypotensive agent and ventricular fibrillation
inductor
[167]
Bufo bufo gargarizans Bufalin NaK+-ATPase inhibitor [165]
Pseudophryne
coriacea
Semi-purified skin
extracts
Hypotensive agent [168]
Rana igromaculata Bradykinin Hypotensive agent and smooth muscle
exciting substance
[11]
Rana margaratae Margaratensin Neurotensin-like peptide [164]
Cinobufagin NaK+ATPase inhibitor [165]
Rana temporaria Bradykinin Hypotensive agent and smooth muscle
exciting substance
[11]
Bees and Wasps Apis mellifera Cardiopep Beta-adrenergio-like stimulant and anti-
arrhythmic agent
[185]
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Vespa basalis Mastoparan B Anti-hypertensive agent [186]
Toxins acting on hemostasis
Snakes Agkistrodon
rhodostoma
Ancrod Anticoagulant and defibrinogenating agent
(Viprinex®)
[34]
Bothrops alternatus Bhalternin Treatment and prevention of thrombotic
disorders
[35]
Bothrops atrox Batroxobin Anticoagulant and defibrinogenating agent
(Defibrase®)
[33]
Mixture of a TLE with a
thromboplastin-like
enzyme
Treatment of hemorrhages
(Haemocoagulase®)
[13]
Bothrops erythromelas BE-I-PLA2 Antiplatelet agent [39]
Bothrops leucurus BleucMP Treatment and prevention of cardiovascular
disorders and strokes
[36]
Leucurogin Antiplatelet agent [32]
Echis carinatus Echistatin Antiplatelet agent [30]
Sisturus miliaris
barbouri
Barbourin Antiplatelet agent [31]
Trimeresurus
malabaricus
Trimarin Treatment and prevention of thrombotic
disorders
[38]
Vipera lebetina VLH2 Treatment and prevention of thrombotic
disorders
[37]
Spiders Loxosceles. Phospholipase-D Platelet aggregation inductor [149]
Toads and Frogs Bombina maxima Bm-ANXA2 Antiplatelet agent [169]
Bees and Wasps Bombus hypocrita
sapporoensis Bs-VSP
Prothrombin activator, thrombin-like
protease and a plasmin-like protease agent [190]
Bombus ignites Bi-VSP
Prothrombin activator, thrombin-like
protease and a plasmin-like protease agent [188]
Bi-KTI Plasmin inhibitor agent [187]
Bombus terrestris Bt-VSP Prothrombin activator, thrombin-likeprotease and a plasmin-like protease agent [189]
Vespa orientalis Protease I Anticoagulant agent [192]
Vespa magnifica Magnifin Inductor platelet aggregation agent [193]Magnvesin Anticoagulant agent [191]
Ants, Centipedes
and Caterpillars
Lonomia achelous Lonomin V Inhibitor platelet aggregation agent [236]
Lonomia obliqua
Lopap Prothrombin activator agent [233]
Lonofibrase Fibrinogenolytic and fibrinolytic agent Agent [234]
Losac Procoagulant agent [235]
Toxins with antibiotic activity
Snakes Bothrops alternatus Balt-LAAO-I Anti-bacterial agent [42]
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Bothrops asper Myotoxin II Anti-bacterial agent [50]
Bothrops jararaca LAAO Antiparasitic agent [48]
Bothrops marajoensis BmarLAAO Anti-bacterial, antifungal and antiparasitic
agent
[47]
Bothrops neuwiedi Neuwiedase Antiparasitic agent [55]
Bothrops pirajai BpirLAAO-I Anti-bacterial and antiparasitic agent [44]
Bungarus fasciatus BFPA Anti-bacterial agent [53]
Crotalus durissus
cascavella
Casca LAO Anti-bacterial agent [45]
Crotalus durissus
terrificus
Crotoxin Antiviral agent [56]
PLA2-CB Antiviral agent [56]
PLA2-IC Antiviral agent [56]]
Echis carinatus EcTx-I Anti-bacterial agent [51]
Naja atra Vgf-1 Anti-bacterial agent [54]
Naja naja oxiana LAAO Anti-bacterial agent [46]
Porthidium nasutum PnPLA2 Anti-bacterial agent [52]
Trimeresurus jerdonii TJ-LAO Anti-bacterial agent [41]
Trimeresurus
mucrosquamatus
TM-LAO Anti-bacterial agent [43]
Scorpions Hadrurus aztecus Hadrurin Anti-bacterial agent [110]
Leiurus
quinquestriatus
Defensin Anti-bacterial agent [102]
Opistophthalmus
carinatus
Opistoporin I/II Anti-bacterial and antifungal agent [106]
Pandinus imperator Pandinin I/II Antimicrobial agent [101]
Scorpine Anti-bacterial and antiparasitic agent [104]
Parabuthus schlechteri Cationic amphipatic
peptide
Antimicrobial agent [109]
Tityus discrepans Bactridines Anti-bacterial agent [111]
Spiders Lycosa carolinensis Lycotoxins I/II Antimicrobial agent [150]
Toads and Frogs Bufo bufo gargarizans 6-methyl-
spinaceamine
Anti-bacterial agent [172]
Bufalin Antiviral agent [173]
Cinobufagin Antiviral agent [173]
Bufo rubescens Telocinobufagin Anti-bacterial agent [170]
Marinobufagin Anti-bacterial agent [170]
Leptodactylus
pentadactylus
Apinaceamine Anti-bacterial agent [172]
Leptodactylus syphax SPXs Anti-bacterial agent [171]
Rhinella jimi Telocinobufagin Antiparasitic agent [174]
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Hellebrigenin Antiparasitic agent [174]
Bees and Wasps Apis mellifera Melittin Anti-bacterial agent [195]
Bombus ignites Bi-Bombolitin Anti-bacterial and antifungal agent [196]
Osmia rufa Osmin Anti-bacterial and antifungal agent [197]
Vespa bicolor MP-VB1 Anti-bacterial and antifungal agent [198]VESP-VB1 Anti-bacterial and antifungal agent [198]
Ants, Centipedes
and Caterpillars
Myrmecia pilosula Pilosulin 1 Anti-bacterial and antifungal agent [239]
Scolopendra
subspinipes mutilan
Scolopin 1 Anti-bacterial and antifungal agent [240]
Scolopin 2 Anti-bacterial and antifungal agent [240]
Toxins acting on inflammatory and nociceptive responses
Snakes Crotalus durissus
terrificus
Crotamine Antinociceptive agent [63]
Crotoxin Antinociceptive agent [64]
Hyal Anti-edematogenic agent [59]
Lachesis muta βPLI Phospholipase inhibitor [58]
Naja atra Cobrotoxin Antinociceptive agent [65]
Ophiophagus hannah Hannalgesin Antinociceptive agent [66]
Scorpions Buthus martensii BmKIT2 Antinociceptive agent [115]
J123 peptide K+ channel blocker [112]
Spiders Loxosceles laeta SMase D Pro-inflammatory agent [152]
Loxosceles reclusa Phospholipase D Pro-inflammatory agent [152]
Psalmopoeus
cambridgei
Psalmotoxin 1 Antinociceptive and anti-inflammatory agent [151]
Toads and Frogs Epipedobates tricolor Epibatidine Antinociceptive agent [175]
Phyllomedusa sp Deltorphins Opioid analgesic agents [176]
Dermorphins Opioid analgesic agents [61]
Bees and Wasps Apis mellifera Melittin Anti-inflammatory agent [202]MCDP Anti-inflammatory agent [204]
Ants, Centipedes
and Caterpillars
Pseudomyrex
triplarinus Myrmexins Anti-inflammatory agent [242]
Toxins acting on immunological system
Snakes Crotalus durissus
terrificus
Crotapotin Immunossupressive agent [69]
Crotoxin Immunossupressive agent [68]
Ophiophagus hannah OVF Complement system activator agent [71]
Scorpions Androctonus
mauretanicus
Kaliotoxin Ca2+ activated K+ channel [121]
Centruroides limbatus Hongotoxin K+ channel blocker [123]
Centruroides
margaritatus
Margatoxin Immunosuppressive agent [120]
Centruroides noxius Noxiustoxin K+ channel blocker [124]
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Leiurus
quinquestriatus
Agitoxin I/II/III K+ channel blocker [122]
Orthochirus
scrobiculosus
OSK1 Immunosuppressive agent [119]
Pandinus imperator Pi1 K+ channel blocker [125]
Spiders Loxosceles laeta SMase D Antiserum [155]
Loxosceles reclusa SMase D Antiserum [155]
Bees and Wasps Agelaia pallipes
pallipes Protonectin 1-6 Chemotactic agent [211]
Apis mellifera
Api m 1 Allergen [213]
Api m 2 Allergen [213]
Api m 6 Allergen [206]
Pimpla
hypochondriaca
rVPr1 Immunosuppressive agent [210]
rVPr3 Immunosuppressive agent [210]
Polistes annularis Pol a 5 Allergen [213]
Polistes gallicus
Vesp c 1
(phospholipase A1) Allergen
[207-20
8]
Vesp c 5 (antigen-5) Allergen [207-208]
Polybia paulista Polybia-MPI Chemotactic agent [212]Polybia-CP Chemotactic agent [212]
Vespa magnifica
Vesp ma 2 Allergen agent [207-208]
Vesp ma 5 Allergen [207-208]
Vespula germanica Ves g 5 Allergen [213]
Vespula vulgaris Ves v 5 Allergen [213]
Ants, Centipedes
and Caterpillars
Solenopsis invicta
Sol i I Allergen [244]
Sol i II Allergen [243]
Sol i III Allergen [243]
Sol i IV Allergen [243]
Toxins with anticancer and cytotoxic activity
Snakes Agkistrodon acutus Accutin Anticancer agent: disintegrin [73]
ACTX-6 Anticancer agent: L-amino acid oxidase [82]
Agkistrodon contortrix Contortrostatin Anticancer agent: disintegrin [75]
Agkistrodon halys
brevicaudus
Salmosin Anticancer agent: disintegrin [74]
Bothrops brazili sPLA2 Anticancer agent [86]
Bothrops jararacussu BJcuL Anticancer agent [89]
Bothrops leucurus Bl-LAAO Anticancer agent [84]
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Metalloproteinase Anticancer agent [90]
Lectin Anticancer agent [91]
Bothrops neuwiedii sPLA2 Anticancer agent [85]
Calloselasma
rhodostoma
Rhodostomin Anticancer agent: disintegrin [78]
Crotalus atrox Crotatroxin Anticancer agent: disintegrin [77]
Naja naja Disintegrin Anticancer agent [79]
Naja naja naja sPLA2 Anticancer agent [87]
Ophiophagus hannah LAAO Anticancer agent [81]
Trimeresurus
flavoviridis
OHAP-1 Anticancer agent: L-amino acid oxidase [83]
Trimeresurus jerdonii Jerdonin Anticancer agent: disintegrin [76]
Scorpions Heterometrus
bengalensis
Bengalin Anticancer agent [116]
Leiurus
quinquestriatus
Chlorotoxin Anticancer agent [126]
rBmK CTa Anticancer agent [130]
Tityus discrepans Neopladine 1 and 2 Anticancer agent [131]
Spiders Acanthoscurria
gomesiana
Gomesin Cytotoxic and anticancer agent [157]
Psalmopoeus
cambridgei
Psalmotoxin 1 Anticancer agent [156]
Toads and Frogs Bombina variegata
pachypus
Cutaneous venom Anticancer agent [180]
Bufo bufo gargarizans Bufalin Anticancer agent [178]
Cinobufagin Anticancer agent [178]
Formosan Ch’an Su Bufotalin Anticancer agent [179]
Rana ridibunda Brevinin-2R Anticancer agent [181]
Venenum Bufonis CBG Anticancer and immunotherapeutic agent to
treat immune-mediated diseases
[177]
Bees and Wasps Lasioglossum laticeps Lasioglossins Anticancer agent [219]
Polybia paulista
Polybia-MPI Cytotoxic and antiproliferative agent [223]
Polybia-MP-II Cytotoxic agent (hemolytic activity onerythrocytes) [222]
Polybia-MP-III Cytotoxic agent (hemolytic activity onerythrocytes) [222]
Ants, Centipedes
and Caterpillars
Parafontaria laminata
armigera Glycosphingolipid 7 Anticancer agent [246]
Solenopsis invicta Solenopsin A Anticancer agent [245]
Toxins with insulin releasing activity
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Toads and Frogs Agalychnis litodryas Peptides from skin
secretion
Insulin-releasing activity [182]
Bees and Wasps Wasp venom Mastoparan Stimulator of insulin secretion agent [226]
Toxins with insecticides applications
Scorpions Androctonus australis AaH IT1 Anti-insect agent [142]
Buthotus judaicu Bjα IT Anti-insect agent [137]
Buthus martensii BmKM1 Anti-insect agent [140]
Buthus martensii Bm 32/33 Anti-insect agent [144]
Buthus occitanus Bot IT1 Anti-insect agent [135]
Buthus occitanus
mardochei
Bom III/IV Anti-insect agent [139]
Leiurus
quinquestriatus
Lqhα IT Anti-insect agent [134]
Leiurus
quinquestriatus
hebraeus
Lqh III/ VI/ VII Anti-insect agent [141]
Odonthobuthus doriaeOD1 Anti-insect agent [137]
Spiders Loxosceles arizonica SMase D Anti-insect agent [161]
Loxosceles intermedia LiTxx1/ LiTxx2/ LiTxx3 Anti-insect agent [158]
Paracoelotes luctuosus δ-PaluIT1/ δ-PaluIT2 Anti-insect agent [162]
Phoneutria nigriventer Tx4(6-1) Anti-insect agent [160]
Ants, Centipedes
and Caterpillars Pachycondyla goeldii
Ponericins G1 Insecticide Agent [238]
Ponericins G2 Insecticide Agent [238]
Ponericins family W Insecticide Agent [238]
Table 1. Summary of the main biotechnological/pharmacological applications of toxins from venomous animals.
8. Conclusion
The biodiversity of venoms and toxins made it a unique source of leads and structural tem‐
plates from which new therapeutic agents may be developed. Such richness can be useful to
biotechnology and/or pharmacology in many ways, with the prospection of new toxins in
this field. Venoms of several animal species such as snakes, scorpions, toads, frogs and their
active components have shown potential biotechnological applications. Recently, using mo‐
lecular biology techniques and advanced methods of fractionation, researchers have ob‐
tained different native and/or recombinant toxins and enough material to afford deeper
insight into the molecular action of these toxins. The mechanistic elucidation of toxins as
well as their use as drugs will depend on insight into toxin biochemical classification, struc‐
ture/conformation determination and elucidation of toxin biological activities based on their
molecular organization, in addition to their mechanism of action upon different cell models
as well as their cellular receptors. Furthermore, expansions in the fields of chemistry and bi‐
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ology have guided new drug discovery strategies to maximize the identification of biotech‐
nological relevant toxins. In fact, with so much diversity in the terrestrial fauna to be
explored in the future, is extremely important providing a further stimulus to the preserva‐
tion of the precious ecosystem in order to develop the researches focusing on identify and
isolate new molecules with importance in biotechnology or pharmacology.
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